Technology
Health
Biotechnology
Natera
$20.339876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$20.33
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.77 (3.91%) Today
+$0.77 (3.91%) Today
Why Robinhood?
You can buy or sell Natera and other stocks, options, ETFs, and crypto commission-free!
About
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception and Non-Invasive Paternity Testing. Read More The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.
Employees
975
Headquarters
San Carlos, California
Founded
2003
Market Cap
1.21B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
566.15K
High Today
$20.53
Low Today
$19.62
Open Price
$19.62
Volume
419.28K
52 Week High
$29.62
52 Week Low
$8.60
Collections
Technology
Health
Biotechnology
2015 IPO
US
North America
News
Seeking AlphaMar 17
Week In Review: Inventis Closes $70 Million Financing To Develop 30 Novel Therapeutics
Deals and Financings InventisBio of Shanghai closed a $70 million Series C financing co-led by Advantech Capital and CMBI, followed by Pudong Innotek (see story). Founded in 2013, InventisBio focuses on discovering and developing novel therapeutics for cancer and metabolic diseases. The company has close to 30 programs in development, including two under China NDA review. Previously, InventisBio raised $25 million in two venture rounds led by Lilly Asia Venture and OrbiMed Asia, which both participated in ...
Seeking AlphaMar 14
Natera, Inc. 2018 Q4 - Results - Earnings Call Slides
The following slide deck was published by Natera, Inc. in conjunction with their 2018 Q4 earnings call. 1 17 Click to enlarge Notes:...
The Motley FoolMar 13
Here's Why Natera Rose as Much as 24.7% Today
What happened Shares of Natera (NASDAQ:NTRA) jumped nearly 25% today after the company announced fourth-quarter and full-year 2018 operating results. The business delivered impressive growth last year -- as did its genetic testing peers -- and expects that momentum to carry into 2019. That's partly due to a potentially lucrative partnership with China's genomics powerhouse, BGI, which was announced the day before. The genetic testing player will receive a net up-front payment of $44 million plus royalties ...
Price Paid on Robinhood
16% Higher
Right Now
52 Week Low
$8.60
Average Price Paid
$17.57
52 Week High
$29.62
Earnings
-$0.85
-$0.72
-$0.59
-$0.46
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.52 per share
Actual
-$0.51 per share